Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic Factors

Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic Factors | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic Factors Mateusz Bilski, Georges Noël, Krzysztof Smółka, Katarzyna Kuncewicz, and 20 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7003502/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 30 Oct, 2025 Read the published version in Scientific Reports → Version 1 posted 10 You are reading this latest preprint version Abstract The 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n = 45, grade 3: n = 51, grade 4: n = 83) treated with surgery and radio(chemo)therapy across four centers in Poland and France. Chemotherapy was administered to 74.9% of patients, with a median radiotherapy dose of 60 Gy (range 32.5–80 Gy). IDH1/2 mutations were identified in 55.3% and 1p/19q codeletion in 22.4%. Patients with IDH1/2 mutations had significantly longer progression-free survival (PFS, 7.7 vs. 1.0 years) and overall survival (OS, 8.2 vs. 2.5 years), both p < 0.01. 1p/19q codeletion was associated with prolonged PFS (7.7 vs. 1.6 years, p < 0.01). In grade 3 gliomas, chemotherapy improved PFS (6.8 vs. 3.6 years) and OS (6.9 vs. 3.9 years), both p < 0.01. Leukopenia grade 0–2 correlated with better PFS (3.6 vs. 1.2 years, p = 0.02) and OS (7.2 vs. 3.2 years, p = 0.04). Absolute lymphocyte count ≤ 1×10³/mm³ predicted worse OS (5.3 vs. 8.7 years, p = 0.0043). CTV < 127 cm³ predicted longer OS in grade 4 gliomas (3.2 vs. 1.7 years, p = 0.012). Our findings provide new real-world evidence on survival and prognostic factors in this population, for which contemporary RWE and OS/PFS data remain scarce. Biological sciences/Cancer Health sciences/Oncology Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 30 Oct, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 14 Aug, 2025 Reviews received at journal 13 Aug, 2025 Reviews received at journal 12 Aug, 2025 Reviewers agreed at journal 03 Aug, 2025 Reviewers agreed at journal 03 Aug, 2025 Reviewers invited by journal 28 Jul, 2025 Editor assigned by journal 28 Jul, 2025 Editor invited by journal 24 Jul, 2025 Submission checks completed at journal 04 Jul, 2025 First submitted to journal 04 Jul, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7003502","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":493203327,"identity":"7ecf583a-52c7-48d7-873c-6956ef3c5136","order_by":0,"name":"Mateusz Bilski","email":"","orcid":"","institution":"Saint John's Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Mateusz","middleName":"","lastName":"Bilski","suffix":""},{"id":493203328,"identity":"76dcb0b7-c14d-4bc4-9020-ff5072ac5dbc","order_by":1,"name":"Georges Noël","email":"","orcid":"","institution":"Strasbourg Europe Cancer Institute (ICANS)","correspondingAuthor":false,"prefix":"","firstName":"Georges","middleName":"","lastName":"Noël","suffix":""},{"id":493203329,"identity":"06f8647e-7c59-4f0b-9d01-0a1c8bb8603b","order_by":2,"name":"Krzysztof Smółka","email":"","orcid":"","institution":"Lodz University of Technology","correspondingAuthor":false,"prefix":"","firstName":"Krzysztof","middleName":"","lastName":"Smółka","suffix":""},{"id":493203330,"identity":"5bd77972-323d-4b5d-b794-fdf82d5e3f71","order_by":3,"name":"Katarzyna Kuncewicz","email":"","orcid":"","institution":"Saint John's Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Katarzyna","middleName":"","lastName":"Kuncewicz","suffix":""},{"id":493203331,"identity":"08fecee2-ec3b-4899-b50d-8c707adc2517","order_by":4,"name":"Wojciech Kuźnicki","email":"","orcid":"","institution":"Medical University of Lodz","correspondingAuthor":false,"prefix":"","firstName":"Wojciech","middleName":"","lastName":"Kuźnicki","suffix":""},{"id":493203332,"identity":"dc1bea4a-7950-441c-9941-590c6410753e","order_by":5,"name":"Loic Feuvret","email":"","orcid":"","institution":"Hospices Civils de Lyon, Hospital Pierre Wertheimer, Hospices Civils de Lyon","correspondingAuthor":false,"prefix":"","firstName":"Loic","middleName":"","lastName":"Feuvret","suffix":""},{"id":493203333,"identity":"4cf63025-70c0-4e6c-906c-4095af805cef","order_by":6,"name":"Katarzyna Korab","email":"","orcid":"","institution":"Saint John's Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Katarzyna","middleName":"","lastName":"Korab","suffix":""},{"id":493203334,"identity":"2122106e-b8ca-4e44-9858-28786944b8f4","order_by":7,"name":"Magdalena Peszyńska-Piorun","email":"","orcid":"","institution":"Copernicus Memorial Hospital in Łódź","correspondingAuthor":false,"prefix":"","firstName":"Magdalena","middleName":"","lastName":"Peszyńska-Piorun","suffix":""},{"id":493203335,"identity":"edda833a-9fa6-4039-bc7e-37d7615b9060","order_by":8,"name":"Paweł Korona","email":"","orcid":"","institution":"Saint John's Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Paweł","middleName":"","lastName":"Korona","suffix":""},{"id":493203336,"identity":"61372c54-953b-4829-b233-b8ad50704d8f","order_by":9,"name":"Izabela Baranowska","email":"","orcid":"","institution":"Saint John's Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Izabela","middleName":"","lastName":"Baranowska","suffix":""},{"id":493203337,"identity":"cb74d379-b5db-4e16-a388-f1aec75ff570","order_by":10,"name":"Agata Suleja","email":"","orcid":"","institution":"Medical University of Vienna","correspondingAuthor":false,"prefix":"","firstName":"Agata","middleName":"","lastName":"Suleja","suffix":""},{"id":493203338,"identity":"9938b4e7-5a7a-4caa-9807-1529b4405d1d","order_by":11,"name":"Clara Le Fevre","email":"","orcid":"","institution":"Strasbourg Europe Cancer Institute (ICANS)","correspondingAuthor":false,"prefix":"","firstName":"Clara","middleName":"Le","lastName":"Fevre","suffix":""},{"id":493203339,"identity":"6fd28d96-f78b-4dd6-a743-13222ff8cf72","order_by":12,"name":"Roland Schott","email":"","orcid":"","institution":"Strasbourg Europe Cancer Institute (ICANS)","correspondingAuthor":false,"prefix":"","firstName":"Roland","middleName":"","lastName":"Schott","suffix":""},{"id":493203340,"identity":"46a46e2d-8af2-4b2b-8d15-b502dad00216","order_by":13,"name":"Laura Somme","email":"","orcid":"","institution":"Strasbourg Europe Cancer Institute (ICANS)","correspondingAuthor":false,"prefix":"","firstName":"Laura","middleName":"","lastName":"Somme","suffix":""},{"id":493203341,"identity":"df483f88-f3a9-43cf-ab3c-b5fcf884e6cb","order_by":14,"name":"Salma Chabli","email":"","orcid":"","institution":"CHU Mohammed VI","correspondingAuthor":false,"prefix":"","firstName":"Salma","middleName":"","lastName":"Chabli","suffix":""},{"id":493203342,"identity":"fe13a2e2-88f8-4d48-bb56-4c4746ba447c","order_by":15,"name":"Emmanuel Mesny","email":"","orcid":"","institution":"Hospices Civils de Lyon, Hospital Pierre Wertheimer, Hospices Civils de Lyon","correspondingAuthor":false,"prefix":"","firstName":"Emmanuel","middleName":"","lastName":"Mesny","suffix":""},{"id":493203343,"identity":"ecb7b992-4261-4d92-ba82-17bfa1bc844b","order_by":16,"name":"Federico Mastroleo","email":"","orcid":"","institution":"European Institute of Oncology IRCCS","correspondingAuthor":false,"prefix":"","firstName":"Federico","middleName":"","lastName":"Mastroleo","suffix":""},{"id":493203344,"identity":"1b91fa01-f500-485a-83fa-08ab12a5daf4","order_by":17,"name":"Rupesh Kotecha","email":"","orcid":"","institution":"Miami Cancer Institute, Baptist Health South Florida","correspondingAuthor":false,"prefix":"","firstName":"Rupesh","middleName":"","lastName":"Kotecha","suffix":""},{"id":493203345,"identity":"1047dd1d-acd8-4253-b74b-b36a9a49651b","order_by":18,"name":"Jakub Jurkiewicz","email":"","orcid":"","institution":"Affidea NU-MED Cancer Diagnostic and Therapy Center","correspondingAuthor":false,"prefix":"","firstName":"Jakub","middleName":"","lastName":"Jurkiewicz","suffix":""},{"id":493203346,"identity":"fb8dc576-25a3-4bc3-ae4d-9418c204995d","order_by":19,"name":"Jacek Fijuth","email":"","orcid":"","institution":"Medical University of Lodz","correspondingAuthor":false,"prefix":"","firstName":"Jacek","middleName":"","lastName":"Fijuth","suffix":""},{"id":493203347,"identity":"7bb13dc9-2190-4355-b667-fb086471c3ee","order_by":20,"name":"Barbara Alicja Jereczek-Fossa","email":"","orcid":"","institution":"European Institute of Oncology IRCCS","correspondingAuthor":false,"prefix":"","firstName":"Barbara","middleName":"Alicja","lastName":"Jereczek-Fossa","suffix":""},{"id":493203348,"identity":"c8de006e-8b6f-45cc-b92d-3b786059f3f6","order_by":21,"name":"Kamil Krystkiewicz","email":"","orcid":"","institution":"Copernicus Memorial Hospital in Łódź","correspondingAuthor":false,"prefix":"","firstName":"Kamil","middleName":"","lastName":"Krystkiewicz","suffix":""},{"id":493203349,"identity":"e4eab13c-fb11-4015-b199-5350f6e39474","order_by":22,"name":"Maciej Harat","email":"","orcid":"","institution":"Franciszek Lukaszczyk Oncology Center","correspondingAuthor":false,"prefix":"","firstName":"Maciej","middleName":"","lastName":"Harat","suffix":""},{"id":493203354,"identity":"54329c74-7242-4838-9952-4277c988264f","order_by":23,"name":"Łukasz Kuncman","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABDUlEQVRIie3QPWvCQBjA8acEzuXU9ST1O1wJZDHoV8khnIuDY0dL4Jz0mxTsEjqeBNIltOuFFOpSpxbaLYKFHomLxSsZC73/cjzD794AbLY/WAdQtdLjHNTDFhy9OvNzBP0gvB7Cilw0IkkDQjj7LA/g0SJ6Xe/vn9jtIlpDeD0YgXtjIomLMfj0OfXzZVawOEtnEGYTBy43BjKZu0AgoGqKVFtooqYUmEgQEGYi0b6kNcm/xCOLX94qgs2EpwSH+mKaFG0h9Sm4IsRI8I4PsCReT3G/6IuxF2d8JvVbKDK8pdviXl4egquVGu/ydzHsxw/J3fZD/1jXjeQ5coycjrK+8y+g2T42m832b/sGZp9iR1ykACwAAAAASUVORK5CYII=","orcid":"","institution":"Medical University of Lodz","correspondingAuthor":true,"prefix":"","firstName":"Łukasz","middleName":"","lastName":"Kuncman","suffix":""}],"badges":[],"createdAt":"2025-06-29 15:08:19","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7003502/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7003502/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-025-21934-2","type":"published","date":"2025-10-30T15:58:47+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":95041477,"identity":"957087b4-3f4e-4070-be7c-8a5afa498122","added_by":"auto","created_at":"2025-11-03 16:11:43","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1155352,"visible":true,"origin":"","legend":"","description":"","filename":"RWSurvivalOutcomesAfterChemoradiotherapyforWHO2021ClassifiedGliomasOne.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7003502/v1_covered_621f47c7-e953-4c2b-b875-cd6576051895.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic Factors","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7003502/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7003502/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe 2021 WHO glioma classification integrates molecular profiling, but outcome data for these patients are limited. We retrospectively analyzed 179 patients (median age 53) with WHO 2021-classified gliomas (grade 2: n\u0026thinsp;=\u0026thinsp;45, grade 3: n\u0026thinsp;=\u0026thinsp;51, grade 4: n\u0026thinsp;=\u0026thinsp;83) treated with surgery and radio(chemo)therapy across four centers in Poland and France. Chemotherapy was administered to 74.9% of patients, with a median radiotherapy dose of 60 Gy (range 32.5\u0026ndash;80 Gy). IDH1/2 mutations were identified in 55.3% and 1p/19q codeletion in 22.4%. Patients with IDH1/2 mutations had significantly longer progression-free survival (PFS, 7.7 vs. 1.0 years) and overall survival (OS, 8.2 vs. 2.5 years), both p\u0026thinsp;\u0026lt;\u0026thinsp;0.01. 1p/19q codeletion was associated with prolonged PFS (7.7 vs. 1.6 years, p\u0026thinsp;\u0026lt;\u0026thinsp;0.01). In grade 3 gliomas, chemotherapy improved PFS (6.8 vs. 3.6 years) and OS (6.9 vs. 3.9 years), both p\u0026thinsp;\u0026lt;\u0026thinsp;0.01. Leukopenia grade 0\u0026ndash;2 correlated with better PFS (3.6 vs. 1.2 years, p\u0026thinsp;=\u0026thinsp;0.02) and OS (7.2 vs. 3.2 years, p\u0026thinsp;=\u0026thinsp;0.04). Absolute lymphocyte count\u0026thinsp;\u0026le;\u0026thinsp;1\u0026times;10\u0026sup3;/mm\u0026sup3; predicted worse OS (5.3 vs. 8.7 years, p\u0026thinsp;=\u0026thinsp;0.0043). CTV\u0026thinsp;\u0026lt;\u0026thinsp;127 cm\u0026sup3; predicted longer OS in grade 4 gliomas (3.2 vs. 1.7 years, p\u0026thinsp;=\u0026thinsp;0.012). Our findings provide new real-world evidence on survival and prognostic factors in this population, for which contemporary RWE and OS/PFS data remain scarce.\u003c/p\u003e","manuscriptTitle":"Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic Factors","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-31 19:53:39","doi":"10.21203/rs.3.rs-7003502/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-08-14T09:22:21+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-13T20:06:44+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-08-12T20:04:28+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"117819617665422142089814259247352632537","date":"2025-08-03T13:19:41+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"18384772463005786723539781151845609829","date":"2025-08-03T08:25:19+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-07-28T12:07:52+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-07-28T11:59:11+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-07-25T03:34:01+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-07-04T16:53:03+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-07-04T16:48:12+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"9134636f-6a90-4206-a5a2-102ca7034030","owner":[],"postedDate":"July 31st, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":52373982,"name":"Biological sciences/Cancer"},{"id":52373983,"name":"Health sciences/Oncology"}],"tags":[],"updatedAt":"2025-11-03T16:11:24+00:00","versionOfRecord":{"articleIdentity":"rs-7003502","link":"https://doi.org/10.1038/s41598-025-21934-2","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-10-30 15:58:47","publishedOnDateReadable":"October 30th, 2025"},"versionCreatedAt":"2025-07-31 19:53:39","video":"","vorDoi":"10.1038/s41598-025-21934-2","vorDoiUrl":"https://doi.org/10.1038/s41598-025-21934-2","workflowStages":[]},"version":"v1","identity":"rs-7003502","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7003502","identity":"rs-7003502","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}